Insulet Corrects Omnipod 5 Pods After Defect Leads to Hospitalizations

ACTON, Mass. – March 12, 2026 – Insulet Corporation has initiated a voluntary Medical Device Correction for specific lots of its popular Omnipod® 5 automated insulin delivery pods in the United States after a manufacturing defect has been linked to at least 18 serious adverse health events, including hospitalizations for diabetic ketoacidosis (DKA).

The company announced that the issue stems from a small tear that can occur in the internal tubing of the wearable, disposable pods. This defect can cause insulin to leak inside the device instead of being delivered to the user, leading to potentially dangerous under-dosing. For individuals with diabetes who rely on the system for continuous insulin infusion, this failure can cause severe high blood glucose (hyperglycemia) and, in the most serious cases, DKA—a life-threatening condition requiring immediate medical attention. No deaths have been reported in connection with the issue.

Insulet, a leader in the tubeless insulin pump market, stated that the affected pods constitute approximately 1.5% of its annual global Omnipod® 5 production. The company has notified the U.S. Food and Drug Administration (FDA) of the action and stressed that all other Omnipod® products, including unaffected lots of Omnipod® 5 pods, remain safe to use.

The Human Impact of a Technical Flaw

For the hundreds of thousands of people who use automated insulin delivery (AID) systems, trust in the technology is paramount. These devices are not conveniences but life-sustaining tools that manage a complex chronic condition. The announcement has sent ripples of concern through the diabetes community, where device reliability is a constant topic of discussion.

Reports on patient-focused online forums have previously detailed user experiences with unexplained high blood glucose levels while using the Omnipod 5 system. Some users described needing to replace pods prematurely after witnessing insulin leakage or experiencing glucose spikes that were inconsistent with their diet or activity. These anecdotal reports now have a clear explanation, underscoring the real-world consequences of a seemingly small manufacturing flaw.

"If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin," Insulet confirmed in its press release. The 18 serious adverse events highlight the gravity of such a failure. Diabetic ketoacidosis occurs when the body, starved of insulin, begins to break down fat for fuel at a rapid rate, producing high levels of ketones that turn the blood acidic. It is a medical emergency that can be fatal if not treated promptly.

Insulet has directed customers to a dedicated website, omnipod.com/check-pods, where they can enter the lot number of their pods to see if they are part of the correction. The company has pledged to replace all affected pods at no cost and has made its 24/7 product support line available for questions and assistance. Users are advised to immediately discontinue the use of any pod from an affected lot and switch to a new one from an unaffected batch.

A History of Corrections in a High-Stakes Industry

While Insulet's proactive communication and offer of free replacements are standard crisis management protocols, this event places the company's quality control processes under a microscope. It also adds to a history of post-market corrections that highlight the inherent challenges of manufacturing complex medical devices.

This is not the first time Insulet has had to address issues with its products. In late 2023 and early 2024, the FDA designated a Class I recall—its most serious classification—for the Omnipod 5 Android app due to a software bug that could cause a significant insulin overdose. In 2022, the company issued a correction for the Omnipod 5 controller's charging port, which posed a risk of overheating and burns. Going back further, Insulet has faced recalls related to cannula deployment and needle mechanism failures in older versions of the Omnipod system.

This pattern is not unique to Insulet; competitors in the medical device space have faced similar challenges. However, the recurring nature of these events underscores the immense responsibility that manufacturers bear. In response to the current issue, Insulet stated it has already implemented updates to its manufacturing processes and quality controls to "strengthen detection and prevention."

From a financial perspective, Insulet projects that the correction will cost the company up to $40 million in 2026. However, it has maintained its financial guidance for the year, suggesting confidence that the issue is contained. The stock market reacted mildly to the news, with Insulet's shares (NASDAQ: PODD) showing little change, indicating that investors may view the financial impact as manageable and the company's response as adequate.

Balancing Innovation with Inherent Risk

The incident serves as a stark reminder of the double-edged sword of modern medical technology. The Omnipod® 5 system represents a significant leap forward in diabetes management, offering users freedom from multiple daily injections and the tubing associated with traditional insulin pumps. By integrating with a continuous glucose monitor (CGM), the system automates insulin delivery, helping to stabilize blood sugar with less manual input.

This level of technological sophistication, however, introduces numerous potential points of failure, from software algorithms to the physical integrity of the hardware. The "small tear" in the pod's tubing is a mechanical issue, distinct from the software bugs or battery problems that have plagued other devices, but its impact on patient safety is just as severe.

The rapid pace of innovation in the AID market is a boon for patients, with companies like Insulet continuously rolling out enhancements. Insulet recently secured FDA clearance for algorithm improvements and expanded use of the Omnipod 5 for individuals with type 2 diabetes. Yet, each advancement adds another layer of complexity that must be rigorously tested and monitored. This correction highlights the critical importance of post-market surveillance and the need for companies to have robust systems for identifying and rectifying problems once a product is in the hands of thousands of users. For patients and healthcare providers, it reinforces the need for constant vigilance and education on how to identify and respond to potential device malfunctions.